Sehouli's 2019 publication demonstrated that Ki67 is a prognostic factor and a biomarker for predicting therapy outcomes and complete resection in low-grade serous ovarian cancer [64]. This evidence concerns the gene MKI67 and ovarian serous adenocarcinoma.